Relationship of Grade, Intrinsic Subtype and Clinical Response to Neoadjuvant Chemotherapy In Breast Cancer

Neoadjuvant chemotherapy has become the standard treatment strategy for locally advanced breast cancer. Currently, neoadjuvant chemotherapy was applied empirically; there are no conventional biomarkers that allow for predicting clinical response and benefit from a particular chemotherapy regimen. Studies mention that grade and intrinsic subtypes are predictors for clinical response to chemotherapy. Purpose of this study were to know the relationship of grade, intrinsic subtype, and clinical response to neoadjuvant chemotherapy in breast cancer. Cross-sectional studies by examining breast cancer patients who underwent chemotherapy in Wahidin Sudirohusodo,  a top referral hospital with 913 bed in Makassar Indonesia, from January 2015 to December 2016. Results: During the periods, neoadjuvant chemotherapy have been conducted to 119 breast cancer patients. In the bivariate analysis, we found that grade significantly associated with chemotherapy response obtained p-value = 0.002 (p < 0.005). Clinical response to neoadjuvant chemotherapy based on subtypes was Luminal A 55.2%, Luminal B 61.2 %, Her2 80%, Triple Negative 87.5%. Association of subtype and chemotherapy response was also significant with p-value = 0.056. Conclusion: histopathological grading and Intrinsic subtype were associated with anthracycline-based neoadjuvant chemotherapy response on breast cancer.